Immunosuppression Model Analysis: Principles, Testing Protocols, and Applications

Immunosuppression model analysis is a preclinical in vivo testing platform that evaluates the immunomodulatory potential of health foods, nutraceuticals, probiotics, and pharmaceutical candidates by measuring their capacity to restore immune function in chemically immunosuppressed laboratory animals. Performed by accredited third-party laboratories in accordance with GB health food functional evaluation standards, ISO 10993 immunotoxicology guidance, and Good Laboratory Practice principles, this analysis generates rigorous scientific evidence for product registration, claim substantiation, and research. This article presents the study design, sample types, testing items, analytical methods, and practical applications of immunosuppression model testing.

Technical Overview

Immunosuppression model analysis is a standardized animal-based method used to characterize the immunoregulatory activity of test substances. In this approach, laboratory animals—most commonly BALB/c, ICR, or KM mice—are rendered immunodeficient through administration of a chemotherapeutic or hormonal immunosuppressant, typically cyclophosphamide. The test substance is then administered over a defined period, and a comprehensive battery of immune function endpoints is measured to determine whether the substance can restore suppressed immune parameters toward normal levels.

The induced immunodeficient state provides a sensitive and quantifiable baseline against which immunoenhancing or immunoregulatory activity can be detected with greater statistical power than in normal animals. Measurable domains include immune organ development, humoral immunity, cellular immunity, and nonspecific (innate) immunity. Study design, endpoint selection, and result judgment criteria follow national GB functional food evaluation procedures, ISO 10993-20 principles for immunotoxicology testing, and Good Laboratory Practice (GLP) requirements, ensuring data integrity and regulatory acceptability.

• Chemically induced immunodeficiency creates a reproducible, quantifiable low-immunity baseline
• Multi-domain endpoints cover humoral, cellular, and innate immune function simultaneously
• Randomized, controlled study designs with positive and model control groups support robust interpretation
• GLP-compliant conduct and ISO/IEC 17025 laboratory management ensure report quality and traceability

Testing Samples

Health Foods and Nutraceuticals

Tablets, capsules, softgels, oral liquids, granules, and powders bearing or seeking immune-support claims represent the most frequently submitted sample category. These products are evaluated to support health food registration or record-filing dossiers under applicable GB functional evaluation procedures, which require in vivo substantiation of immune function enhancement claims.

Probiotics and Functional Microbial Products

Lactobacillus and Bifidobacterium strains, multi-strain probiotic formulations, postbiotics, inactivated bacterial preparations, and fermented products are tested to substantiate strain-level immunomodulatory properties for product differentiation, marketing support, and scientific publication.

Pharmaceuticals, Herbal Extracts, and Biological Products

Immunomodulatory drug candidates, polysaccharide and glycoprotein extracts derived from medicinal fungi and botanicals, vaccine adjuvant candidates, and other biological products are evaluated during preclinical development to establish pharmacodynamic activity and dose-response relationships.

Novel Foods, Ingredients, and Other Materials

New food raw materials, functional oligosaccharides, bioactive peptides, marine-derived polysaccharides, plant extracts, and medical device materials or extracts requiring immunotoxicity or immunomodulation assessment under ISO 10993-20 are also within the scope of this testing platform.

Testing Items

A comprehensive immunosuppression model study typically spans four immunological domains, supported by hematological and molecular markers. Testing items are selected according to product category, regulatory objective, and study design considerations.

Immune Organ and Hematological Parameters

• Thymus index and spleen index (organ weight normalized to body weight)
• White blood cell count and differential lymphocyte count
• Body weight trajectory and general health observations

Humoral Immunity Parameters

• Serum hemolysin level (HC50) against sheep red blood cells (SRBC)
• Plaque-forming cell (antibody-secreting cell) assay in splenocytes
• Serum immunoglobulin quantification: IgG, IgM, and IgA

Cellular Immunity Parameters

• Delayed-type hypersensitivity (DTH) response measured by footpad swelling
• ConA-induced T lymphocyte proliferation and LPS-induced B lymphocyte proliferation
• T lymphocyte subsets (CD3+, CD4+, CD8+) and CD4+/CD8+ ratio by flow cytometry

Nonspecific (Innate) Immunity Parameters

• Natural killer (NK) cell activity by lactate dehydrogenase (LDH) release assay
• Mononuclear phagocyte function by carbon clearance test
• Peritoneal macrophage phagocytic rate and phagocytic index against chicken red blood cells

Cytokine and Molecular Markers

• Interleukins IL-2, IL-4, IL-6, IL-10, IFN-gamma, and TNF-alpha in serum or culture supernatant by ELISA
• Secretory IgA in intestinal or bronchoalveolar lavage fluid for mucosal immunity studies

Testing Methods

Model Establishment and Validation

Cyclophosphamide is the most widely used inducing agent, administered by intraperitoneal or subcutaneous injection at validated dose levels, commonly within the range of 50 to 100 mg/kg, on one or more designated study days. Alternative inducing agents include cyclosporine A, dexamethasone, hydrocortisone acetate, and azathioprine, selected according to the immune pathway under investigation. Successful model establishment is verified by confirming significant suppression of immune parameters in the model control group relative to the negative control group before treatment effects are interpreted.

Study Design and Grouping

Standard designs use healthy specific pathogen free (SPF) mice, typically weighing 18 to 22 g at study initiation, randomized into at least five groups: a negative control group, a model control group, a positive control group treated with a reference immunomodulator such as levamisole, and three dose-level groups of the test substance. The test article is generally administered by oral gavage for 30 days for health food evaluations, consistent with GB functional testing procedures. All animal procedures are reviewed and approved by an Institutional Animal Care and Use Committee and follow the 3R principles of replacement, reduction, and refinement.

Humoral Immunity Assays

Animals are immunized with sheep red blood cells, and serum hemolysin is quantified using a complement-dependent hemolysis assay measured spectrophotometrically, with results expressed as the half hemolysis value (HC50). Antibody-secreting cells in the spleen are enumerated by the plaque-forming cell assay. Serum immunoglobulins are quantified by sandwich ELISA using calibrated reference standards.

Cellular Immunity Assays

Delayed-type hypersensitivity is assessed by sensitizing animals with SRBC and subsequently challenging the footpad, with swelling measured by caliper at 24 to 48 hours after challenge. Splenocyte proliferation is quantified by MTT or CCK-8 colorimetric assay following stimulation with concanavalin A for T cells or lipopolysaccharide for B cells, and results are expressed as a stimulation index. Lymphocyte subsets are analyzed by flow cytometry using fluorescently labeled anti-CD3, anti-CD4, and anti-CD8 antibodies.

Nonspecific Immunity Assays

NK cell activity is measured by the LDH release method using YAC-1 target cells at multiple effector-to-target ratios. The carbon clearance test evaluates mononuclear phagocyte function by intravenous administration of colloidal carbon ink followed by blood sampling at two time points, yielding the clearance index and corrected phagocytic index. Peritoneal macrophage phagocytosis is evaluated by ex vivo incubation with chicken red blood cells and microscopic determination of the phagocytic rate and phagocytic index.

Statistical Analysis and Result Judgment

Following verification of normality and homogeneity of variance, inter-group comparisons are performed using one-way analysis of variance with appropriate post-hoc tests, or non-parametric equivalents where indicated. A positive immunomodulatory result requires statistically significant restoration of suppressed endpoints in test groups compared with the model control group (p < 0.05), ideally accompanied by a dose-response relationship and convergence toward negative control values. Health food claim determinations follow the weighted judgment rules of the applicable national functional evaluation procedure, which typically require positive findings across a defined combination of endpoint categories.

Quality Assurance and Compliance

Studies are conducted in GLP-compliant barrier facilities housing SPF animals under controlled temperature, humidity, ventilation, and a 12-hour light/dark cycle. Accredited third-party laboratories operating under ISO/IEC 17025 management systems apply verified analytical instruments, calibrated equipment, batch-controlled reagents, and independent quality assurance audits of study protocols, raw data, and final reports to guarantee traceability and reliability.

Applications

Immunosuppression model analysis supports a broad spectrum of regulatory, commercial, and scientific objectives across the food, pharmaceutical, and biotechnology sectors. Typical applications include:

• Health food registration and record-filing dossiers substantiating immune function enhancement claims
• Probiotic strain screening, characterization, and efficacy substantiation for marketing and peer-reviewed publication
• Preclinical pharmacodynamic evaluation of immunomodulatory drugs, vaccine adjuvants, and biological products
• Immunotoxicity and immunosafety screening of medical device materials and extracts under ISO 10993-20
• Mechanistic research on immune cell populations, cytokine networks, and gut-associated lymphoid interactions
• Comparative efficacy and dose-finding studies that guide formulation optimization during product development

FAQ

Which animal species and strains are most commonly used?

Healthy SPF mice, including BALB/c, ICR, and KM strains, are the primary models because their immune systems are well characterized and their size suits the multi-endpoint assay battery. C57BL/6 mice and Sprague-Dawley or Wistar rats may be used for specific research objectives, subject to protocol justification.

Why is cyclophosphamide the preferred immunosuppressant?

Cyclophosphamide reliably suppresses multiple immune compartments, including leukocyte counts, thymus and spleen mass, antibody production, and lymphocyte proliferation, producing a stable and reproducible hyporesponsive baseline. Its dose-response characteristics are well documented, allowing model parameters to be standardized across studies.

What is the typical duration of a complete study?

Most mouse studies run approximately 4 to 5 weeks, comprising an acclimatization period, a 30-day test substance administration phase concurrent with model induction, immunization and challenge procedures, and terminal sample collection and analysis. Protocol durations may be adjusted for pharmaceutical or research designs.

How is a positive result determined?

A positive result requires statistically significant recovery of one or more suppressed immune parameters in treated groups relative to the model control group, with values approaching those of the negative control. For health food claims, national GB functional evaluation procedures define which endpoint combinations must show improvement for a claim to be supported.

Are the studies ethically reviewed and quality controlled?

Yes. All protocols undergo review and approval by an Institutional Animal Care and Use Committee prior to initiation, and studies are conducted under the 3R principles. Accredited third-party laboratories further apply GLP-compliant procedures and ISO/IEC 17025 management systems, with independent quality assurance oversight of protocols, data, and reports.

Can the model be adapted for special sample types or research questions?

Yes. The basic platform can be customized with alternative immunosuppressants, extended dosing periods, additional cytokine or flow cytometry panels, mucosal immunity endpoints, or combined safety assessments to address the specific requirements of pharmaceutical candidates, probiotics, or novel ingredients.